ClinicalTrials.gg
CompletedNCT00741897Updated Sep 15, 2009

Fexofenadine Study On Filipino Children for The Relief of Perennial And Intermittent Allergic Rhinitis

A Phase 4 interventional study of Fexofenadine in Rhinitis, Allergic, Perennial, sponsored by Sanofi. Completed at 1 site in Philippines. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2009-09-15.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
264
Allocation
Not applicable
Ages
6 Years to 11 Years
Sex
All
01

Study summary

To determine the safety and efficacy of Fexofenadine (Telfast®) 30mg pediatric tablets on Filipino children aged 6 to 11 for the relief of symptoms associated with perennial and intermittent allergic rhinitis.

02

Conditions studied

  • Rhinitis, Allergic, Perennial
03

In context

Rhinitis, Allergic, Perennial

178 studies on the registry are indexed under Rhinitis, Allergic, Perennial; 9 are open to participants now.

This study's enrollment of 264 is above the median of 135 across 157 interventional studies indexed under Rhinitis, Allergic, Perennial.

Browse Rhinitis, Allergic, Perennial studies →

Lead sponsor

Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Children who manifest allergic rhinitis symptoms such as sneezing, rhinorrhea, itchy nose/palate/throat and/or itchy/watery/red eyes.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
264 participants (actual)

Study arms

  • Experimental
    1

    Fexofenadine

    Drug: Fexofenadine

Interventions

  • Fexofenadine: One 30 mg Tablet once daily for two weeks

06

What researchers measure

Primary outcomes

  1. Patient's assessment of symptoms and drug activity (Total symptom scores)

    Time frame: At baseline, D 7 and D 14

  2. Physician's assessment of symptoms and drug activity (Total symptom scores)

    Time frame: At D 14

Secondary outcomes

  1. AE and SAE collection

    Time frame: From the signature of the informed consent up to the end of the study

07

Study locations

1 site
  • Sanofi-aventis administrative office
    Makati City, Philippines
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2002 and a primary completion of Dec 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2008
First posted
Aug 26, 2008
Start
Mar 2002
Primary completionActual
Dec 2003
Last update
Sep 15, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00741897
Lead sponsor
Sanofi
First posted
Aug 26, 2008
Start date
Mar 2002
Primary completion
Dec 2003
Last update
Sep 15, 2009

Study contacts

Carmela Pagunsan
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fexofenadine

Start the discussion